Sera Prognostics Stock Today
| SERA Stock | USD 2.88 0.04 1.37% |
PerformanceWeak
| Odds Of DistressLow
|
Sera Prognostics is trading at 2.88 as of the 22nd of July 2025, a 1.37 percent decrease since the beginning of the trading day. The stock's open price was 2.92. Sera Prognostics has about a 23 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 23rd of April 2025 and ending today, the 22nd of July 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of July 2021 | Category Healthcare | Classification Health Care |
Sera Prognostics, Inc., a womens health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah. Sera Prognostics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 36.7 M outstanding shares of which 1.28 M shares are at this time shorted by private and institutional investors with about 2.43 trading days to cover. More on Sera Prognostics
Moving against Sera Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Sera Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Evguenia MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSera Prognostics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Sera Prognostics' financial leverage. It provides some insight into what part of Sera Prognostics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sera Prognostics (SERA) is traded on NASDAQ Exchange in USA. It is located in 2749 East Parleys Way, Salt Lake City, UT, United States, 84109 and employs 63 people. Sera Prognostics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 110 M. Sera Prognostics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 36.7 M outstanding shares of which 1.28 M shares are at this time shorted by private and institutional investors with about 2.43 trading days to cover.
Sera Prognostics currently holds about 106.91 M in cash with (14.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Sera Prognostics Probability Of Bankruptcy
Ownership AllocationSera Prognostics shows a total of 36.7 Million outstanding shares. Over half of Sera Prognostics' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Sera Ownership Details
Sera Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2025-03-31 | 472.3 K | |
| Northern Trust Corp | 2025-03-31 | 264.9 K | |
| Perkins Capital Management Inc | 2025-03-31 | 150 K | |
| Bank Of New York Mellon Corp | 2025-03-31 | 135.6 K | |
| Ghisallo Capital Management Llc | 2025-03-31 | 100 K | |
| Wealth Enhancement Advisory Services, Llc | 2025-03-31 | 98.8 K | |
| Smh Capital Inc. | 2025-03-31 | 94.2 K | |
| Bridgeway Capital Management, Llc | 2025-03-31 | 90.7 K | |
| Ubs Group Ag | 2025-03-31 | 86.8 K | |
| Baker Bros Advisors Lp | 2025-03-31 | 5.5 M | |
| Ra Capital Management, Llc | 2025-03-31 | 3 M |
Sera Prognostics Historical Income Statement
Sera Stock Against Markets
Sera Prognostics Corporate Management
| Benjamin JD | General Counsel | Profile | |
| Steven Graves | CoFounder Board | Profile | |
| Lee Anderson | Chief Officer | Profile | |
| John Boniface | Chief Officer | Profile | |
| Paul Kearney | Chief Officer | Profile | |
| Robert Harrison | Chief Officer | Profile | |
| Austin Aerts | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sera Prognostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Sera Stock refer to our How to Trade Sera Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sera Prognostics. If investors know Sera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sera Prognostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.94) | Revenue Per Share | Quarterly Revenue Growth (0.41) | Return On Assets | Return On Equity |
The market value of Sera Prognostics is measured differently than its book value, which is the value of Sera that is recorded on the company's balance sheet. Investors also form their own opinion of Sera Prognostics' value that differs from its market value or its book value, called intrinsic value, which is Sera Prognostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sera Prognostics' market value can be influenced by many factors that don't directly affect Sera Prognostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sera Prognostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sera Prognostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sera Prognostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.